Human PSC-Derived SAN-Plexus Assembloids: A Model for Neuro-Cardiac Pacemaker Maturation

Study Background and Research Question

The sinoatrial node (SAN) orchestrates the rhythmic electrical impulses that initiate each heartbeat, serving as the principal pacemaker of the human heart. Its function is modulated by intricate neuro-cardiac interactions, predominantly through autonomic innervation from the cardiac ganglionated plexus. While animal models have elucidated many principles of SAN formation and control, species-specific differences in electrophysiology and innervation limit direct translation to human biology. Further complicating research, human SAN tissue is scarce and structurally complex, and available in vitro models lack both three-dimensional (3D) organization and autonomic inputs. The central research question in the reference study was whether a human-specific, stem cell-derived in vitro platform could reliably recapitulate the structural, molecular, and functional hallmarks of SAN maturation—including the essential neuronal modulation of pacemaker activity.

Key Innovation from the Reference Study

The core innovation presented in this study is the construction of "SAN-plexus assembloids"—multicellular 3D constructs that combine human pluripotent stem cell (hPSC)-derived SAN organoids (SANOs) with cardiac ganglionated plexus organoids (CGPOs), further integrating atrial-like cardiac organoids to model the physiological context of pacemaker-to-atrial conduction. This tri-assembloid system uniquely allows functional interrogation of neuron-to-pacemaker communication and the study of innervation-associated maturation of pacemaker cells. Notably, the model is the first to demonstrate that CGPO-derived prosaposin (PSAP) signaling via the SAN-enriched GPR37 receptor is a key driver of pacemaker maturation, as evidenced by multi-layered functional and transcriptomic analyses (reference study).

Methods and Experimental Design Insights

The research team employed a multi-step differentiation protocol to generate three principal organoid types from hPSCs: SANOs, CGPOs, and atrial-like cardiac organoids. These were assembled into spatially organized 3D assembloids, creating a microenvironment where neuro-cardiac interactions could be directly observed and manipulated. Molecular and functional characterization included:

• Spatial transcriptomics to map gene expression and compare assembloid composition to native human SAN tissue.
• Electrophysiological assays to analyze spontaneous diastolic depolarization and action potential propagation within the assembloid system.
• Functional perturbation of neuron-to-pacemaker signaling, particularly focusing on PSAP-GPR37 engagement.

This integrated approach enabled comprehensive assessment of both the developmental state and functional output of SAN-like pacemaker cells within a human-relevant context.

Core Findings and Why They Matter

The SAN-plexus assembloid platform recapitulated key molecular and structural features of the human SAN, including the presence of distinct pacemaker cell subtypes (head, tail, and transitional populations) and authentic 3D architecture. Functional analyses demonstrated that SANPCs within the assembloids exhibited hallmark electrophysiological properties—namely, spontaneous diastolic depolarization and slow upstroke action potentials—which are essential for pacemaker dominance. Crucially, integration with CGPOs enabled the study of neuronally mediated modulation of pacemaker activity and conduction to atrial tissue. By leveraging spatial transcriptomics, the authors identified a neuron-to-pacemaker signaling axis involving CGPO-derived prosaposin and the GPR37 receptor, which was shown to promote the maturation and functional competence of SAN-like pacemaker cells. These findings establish the assembloid system as a robust platform for dissecting the molecular underpinnings of pacemaker maturation and for modeling congenital or acquired SAN dysfunction in a human context (reference study).

Protocol Parameters

• hPSC differentiation: Sequential induction of SAN and CGPO lineages; timing and growth factor composition as detailed in the study's methods.
• Assembloid formation: Co-aggregation of mature SANOs, CGPOs, and atrial-like organoids in defined ratios to recapitulate physiological spatial organization.
• Electrophysiology analysis: Use of patch-clamp and multielectrode array to assess pacemaker activity and conduction velocity between compartments.
• Signaling perturbation: Application of PSAP or GPR37 antagonists to dissect neuron-to-pacemaker communication pathways.
• Spatial transcriptomics: Integration of in situ spatial mapping to validate cellular heterogeneity and signaling architecture.

Comparison with Existing Internal Articles

A detailed review in "Modeling Human Pacemaker Maturation with SAN-Plexus Assembloids" contextualizes this assembloid model as a breakthrough for studying neuro-cardiac interactions in vitro, emphasizing the system's utility for mechanistic dissection of pacemaker development and disease. By comparison, articles such as "Strategic Use of Cucurbitacin I for Translational STAT3 Research" and "Cucurbitacin I (JSI-124): Precision STAT3 Inhibition in Cancer Models" focus on the pharmacological targeting of signaling pathways—most notably STAT3—in cancer biology. While these resources do not directly address neuro-cardiac development, they underscore the value of highly selective chemical tools and advanced organoid models for dissecting cell-type specific signaling both in oncology and regenerative medicine.

Limitations and Transferability

Although the SAN-plexus assembloid model represents a substantial advance over previous systems, several limitations remain. The platform relies on in vitro differentiation protocols that may not fully recapitulate in vivo microenvironmental cues, and long-term functional stability has yet to be established. The complexity of the native SAN—particularly its vascular and extracellular matrix components—is not fully modeled in current assembloids. Furthermore, while neuron-to-pacemaker interactions are robustly demonstrated, the full spectrum of autonomic modulation (including sympathetic contributions) will require future model expansion. These factors should be considered when extrapolating findings to in vivo or translational settings.

Research Support Resources

For researchers interested in functional dissection of cardiac signaling pathways—including those intersecting with pacemaker cell maturation or disease—selective inhibitors such as Cucurbitacin I (JSI-124, SKU A4512) are valuable reagents for precise pathway interrogation. According to the product information, Cucurbitacin I is a potent and selective JAK2/STAT3 inhibitor, widely used for cancer cell proliferation and invasion assays, as well as for in vivo tumor growth inhibition studies. While its primary applications remain in oncology, its capacity to modulate STAT3-dependent gene expression could be leveraged in advanced organoid or assembloid models to dissect the role of STAT3 in cardiac or neuro-cardiac lineage specification, provided experimental design and controls are carefully considered.